---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-040296"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:41:20.407772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India

## Summary
- Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.
- NanoViricides reimburses all direct/indirect trial costs plus a 30% fee; Karveer pays 70% of invoiced commercial sales to NanoViricides.
- No minimum royalties or license maintenance fees; term continues as long as Karveer uses NanoViricides' proprietary technologies.
- NanoViricides retains full rights to clinical data for use outside India.

## SEC filing metadata
- accession: 0001104659-23-040296
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/0001104659-23-040296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/tm2311179d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-040296
- JSON: https://secwatch.observer/filing/0001104659-23-040296.json
- Plain text: https://secwatch.observer/filing/0001104659-23-040296.txt

## Key facts
- Material Agreements
  NANOVIRICIDES, INC. entered into License Agreement with Karveer Meditech Private Limited (effective 2023-03-27).
  - Action: entry
  - Agreement: license
  - Counterparty: Karveer Meditech Private Limited
  - Effective: 2023-03-27
  source text: On March 27, 2023, NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited (“Karveer”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/0001104659-23-040296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.